In a nutshell This study compared the long-term effects of biological drug pembrolizumab (Keytruda) with chemotherapy drug docetaxel (Taxotere) in patients with advanced non-small cell lung carcinoma (NSCLC). The study found that pembrolizumab increased survival and had fewer side effects than docetaxel. Some background Patients with advanced...
Read MoreType of lung cancer-Non-small cell lung carcinoma (NSCLC) Posts on Medivizor
Adding ramucirumab to erlotinib treatment for patients with advanced non-small cell lung cancer with EGFR mutations
In a nutshell This study wanted to find out if using two kinds of medication together worked better than only one medication to treat advanced non-small cell lung cancer that has not been treated before. The study found that using ramucirumab (Cyramza) with erlotinib (Tarceva) was better than using erlotinib alone. Some background There are a number...
Read MoreEvaluating immune-related side effects associated with pembrolizumab.
In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...
Read MoreCan adding chemotherapy agents to gefitinib improve outcomes for advanced NSCLC?
In a nutshell This study investigated whether adding chemotherapy agents to gefitinib (Iressa) improved outcomes for patients with advanced non-small cell lung cancer (NSCLC). This study found that this combination improved survival but increased side effects for these patients. Some background The gene for epidermal growth factor receptor...
Read MoreEvaluating ALK tyrosine kinase inhibitor drugs for elderly patients with non-small cell lung cancer
In a nutshell This study evaluated the effectiveness and safety of three different ALK tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC). The authors concluded that these inhibitors were similarly effective, but elderly patients over age 65 were more likely to develop side effects. Some background NSCLC is...
Read MoreLooking for patients with advanced non-small cell lung cancer to test a biological therapy.
In a nutshell This trial is examining the effectiveness of pegilodecakin (AM0010) when it is used with pembrolizumab (Keytruda) to treat patients with advanced non-small cell lung cancer (NSCLC). The main outcome to be measured will be tumor responses to the treatment. This trial is recruiting in multiple locations around the United States. The...
Read MoreLong-term survival with nivolumab treatment in non-small cell lung cancer
In a nutshell This study investigated the long-term survival of patients with non-small cell lung cancer (NSCLC) treated with nivolumab (Opdivo). They found that this treatment is well tolerated and improved survival in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common form of lung cancer (LC). Over...
Read MoreSearching for patients with advanced non-small cell lung cancer to test a new combination therapy
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In...
Read MoreChemoradiotherapy versus radiation only – which is more effective in inoperable lung cancer?
In a nutshell This study investigated the effectiveness of radiation therapy (RT) and chemoradiotherapy (CRT) in inoperable non-small cell lung cancer (NSCLC). They found that CRT was more effective than RT alone in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common form of lung cancer (LC)....
Read MoreLooking for participants with metastatic non-small cell lung cancer to test a new immunotherapy
In a nutshell This phase 1 trial is examining the effectiveness of personalized tumor antigens (PTA) in the treatment of different advanced tumors. The main outcomes to be measured will be side effects and disease control. This study is being conducted in Arizona, California, Louisiana and New Jersey, US. The details While the tumor cells are growing,...
Read MoreEvaluating long-term outcomes for stereotactic ablative body radiotherapy for early-stage non-small cell lung cancer.
In a nutshell This study wanted to find out if using stereotactic ablative body radiotherapy (SABR) improves survival in patients with early-stage non-small cell lung cancer (NSCLC). The study found that this treatment resulted in good long-term survival and had few side effects. Some background Stereotactic ablative body radiotherapy (SABR) is...
Read MoreSearching patients with relapsed or unresponsive cancer to test a new medication
In a nutshell This phase 1b/2 trial will investigate the safety of RMC-4630 and cobimetinib (Cotellic) in relapsed or unresponsive solid tumors. The main outcomes will be the number of side effects and the overall response rate. This trial is recruiting in a number of US states. The details Relapsed/refractory (R/R) cancer is a term for...
Read More
